BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cytori Therapeutics, Inc. (CYTX) to Webcast Second Quarter Financial Results on August 8


7/26/2012 8:49:22 AM

SAN DIEGO, CA--(Marketwire - July 26, 2012) - Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its second quarter financial results and business update on Wednesday, August 8, 2012 at 5:00 PM Eastern Time.

The dial-in information is as follows:

Dial-In Number: +1.866.791.6247
Passcode: 4549443

Prior to the webcast at approximately 4:05 PM Eastern Time on August 8, Cytori will issue its second quarter earnings release and post a quarterly shareholder letter to its Investor Relations homepage, which will review Cytori's second quarter performance.

The webcast will be available both live and by replay two hours after the call under "Webcasts" on the Company's Investor Relations website (http://ir.cytori.com).

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. www.cytori.com


Contact:
Megan McCormick
mmccormick@cytori.com
+1.858.875.5279



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES